Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CHAT | P28329 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16499669 | 1.00 | ALDH1A1 (0.78) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| (Z)-1,2-Diphenylethene SCHEMBL27498688 | 0.97 | ALDH1A1 (0.82) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| (Z)-1,2-Diphenylethene SCHEMBL28371714 | 0.94 | ALDH1A1 (0.78) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| SCHEMBL10381868 | 0.93 | ALDH1A1 (0.67) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| SCHEMBL10381869 | 0.93 | ALDH1A1 (0.67) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| Styrene SCHEMBL490169 | 0.91 | ALDH1A1 (0.93) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| Styrene SCHEMBL369036 | 0.88 | ALDH1A1 (1.00) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| Styrene SCHEMBL11144289 | 0.88 | ALDH1A1 (1.00) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| Styrene SCHEMBL6258482 | 0.88 | ALDH1A1 (1.00) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 | |
| Styrene SCHEMBL4986035 | 0.88 | ALDH1A1 (1.00) | ALDH1A1TSHRMAOBNFE2L2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698265-A | Method and apparatus for separating microvesicles | 高丽大学校算学协力团 | 2023-02-03 | — | — | CN | claimed |
| CN-109475822-B | Macroporous or mesoporous polymeric membranes of hollow fiber geometry | 亥姆霍兹中心贺昂有限公司 | 2022-03-22 | — | — | CN | claimed |
| EP-2720768-B1 | PURIFICATION OF BIOLOGICAL PRODUCTS BY CONSTRAINED COHYDRATION CHROMATOGRAPHY | AGENCY SCIENCE TECH & RES (SG) | 2017-04-12 | — | — | EP | claimed |
| WO-2011027210-A1 | A GENERAL PURPOSE SOLVENT-BASED ADHESIVE | STELLENBOSCH UNIVERSITY (ZA) | 2011-03-10 | — | — | WO | claimed |
| US-20090194483-A1 | MICROFLUIDIC DEVICE HAVING MONOLITHIC SEPARATION MEDIUM AND METHOD OF USE | AGILENT TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | claimed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | claimed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | claimed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | claimed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | claimed |
| EP-0622109-B1 | Process for deodorizing a formulation comprising at least one compound bearing a thiol group | OREAL (FR) | 1997-07-30 | — | — | EP | claimed |
| EP-0622109-A1 | Process for deodorizing a formulation comprising at least one compound bearing a thiol group and deodorized formulation thus obtained | L'OREAL (FR) | 1994-11-02 | — | — | EP | claimed |
| EP-3292911-B1 | MICROCHIP AND CHANNEL STRUCTURE FOR THE SAME | SONY GROUP CORP (JP) | 2023-12-13 | — | — | EP | disclosed |
| CN-115999519-A | Ultra-high crosslinking adsorbent containing bionic alkaline functional genes, preparation method and application thereof, and protein-bound toxoid adsorber | 杭州是派生物科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115698265-A | Method and apparatus for separating microvesicles | 高丽大学校算学协力团 | 2023-02-03 | — | — | CN | disclosed |
| US-4428876-A | Process for isolating saponins and flavonoids from leguminous plants | TOKIWA KANPO PHARMACEUTICAL CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
| US-4339442-A | Gynosaponins, their use and a process for preparing the same | TAKEMOTO TSUNEMATSU | 1982-07-13 | — | — | US | disclosed |
| US-4157313-A | HYDROGENATION AND COORDINATION CATALYSTS | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (FR) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | ALDH1A1 1419/4885TSHR 3054/4885MAOB 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.